EP3288585A4 - Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants - Google Patents
Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants Download PDFInfo
- Publication number
- EP3288585A4 EP3288585A4 EP16787110.2A EP16787110A EP3288585A4 EP 3288585 A4 EP3288585 A4 EP 3288585A4 EP 16787110 A EP16787110 A EP 16787110A EP 3288585 A4 EP3288585 A4 EP 3288585A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- immunotherapies
- methods
- small molecule
- novel compositions
- integrin receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002671 adjuvant Substances 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
- 102000006495 integrins Human genes 0.000 title 1
- 108010044426 integrins Proteins 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000003384 small molecules Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562154554P | 2015-04-29 | 2015-04-29 | |
PCT/US2016/029683 WO2016176400A2 (en) | 2015-04-29 | 2016-04-28 | Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3288585A2 EP3288585A2 (en) | 2018-03-07 |
EP3288585A4 true EP3288585A4 (en) | 2019-05-01 |
Family
ID=61024178
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16787110.2A Pending EP3288585A4 (en) | 2015-04-29 | 2016-04-28 | Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants |
Country Status (1)
Country | Link |
---|---|
EP (1) | EP3288585A4 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012068251A2 (en) * | 2010-11-16 | 2012-05-24 | Texas Heart Institute | Agonists that enhance binding of integrin-expressing cells to integrin receptors |
-
2016
- 2016-04-28 EP EP16787110.2A patent/EP3288585A4/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012068251A2 (en) * | 2010-11-16 | 2012-05-24 | Texas Heart Institute | Agonists that enhance binding of integrin-expressing cells to integrin receptors |
Non-Patent Citations (4)
Title |
---|
ALESSANDRA TOLOMELLI ET AL: "Can Integrin Agonists Have Cards to Play against Cancer? A Literature Survey of Small Molecules Integrin Activators", CANCERS, vol. 9, no. 12, 5 July 2017 (2017-07-05), pages 78, XP055531258, DOI: 10.3390/cancers9070078 * |
ANDREW M. SCOTT ET AL: "Antibody therapy of cancer", NATURE REVIEWS. CANCER, vol. 12, no. 4, 1 April 2012 (2012-04-01), GB, pages 278 - 287, XP055531673, ISSN: 1474-175X, DOI: 10.1038/nrc3236 * |
M. A. SCHWARTZ ET AL: "Integrin Agonists as Adjuvants in Chemotherapy for Melanoma", CLINICAL CANCER RESEARCH, vol. 14, no. 19, 1 October 2008 (2008-10-01), US, pages 6193 - 6197, XP055531739, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-08-1285 * |
SIMON L GOODMAN ET AL: "Integrins as therapeutic targets", TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 33, no. 7, 1 July 2012 (2012-07-01), pages 405 - 412, XP028495741, ISSN: 0165-6147, [retrieved on 20120412], DOI: 10.1016/J.TIPS.2012.04.002 * |
Also Published As
Publication number | Publication date |
---|---|
EP3288585A2 (en) | 2018-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3350165A4 (en) | Farnesoid x receptor agonists and uses thereof | |
EP3355954A4 (en) | Delivery methods and compositions | |
EP3337907A4 (en) | Microdroplet-based multiple displacement amplification (mda) methods and related compositions | |
EP3350164A4 (en) | Farnesoid x receptor agonists and uses thereof | |
EP3548476A4 (en) | Ire1 small molecule inhibitors | |
EP3099677A4 (en) | Diaminopyrimidine benzenesulfone derivatives and uses thereof | |
IL255297B (en) | Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants | |
EP3125884A4 (en) | Small molecule inhibitors of mcl-1 and uses thereof | |
EP3350166A4 (en) | Farnesoid x receptor agonists and uses thereof | |
EP3380970A4 (en) | Novel azole derivatives as apelin receptor agonist | |
EP3316909A4 (en) | Anti-ntb-a antibodies and related compositions and methods | |
EP3350158A4 (en) | Farnesoid x receptor agonists and uses thereof | |
EP3129048A4 (en) | Antibodies, pharmaceutical compositions and uses thereof | |
EP3503879A4 (en) | Compositions and methods thereof | |
EP3352800A4 (en) | Methods and compositions for reducing metastases | |
EP3150578A4 (en) | Novel pyrrolidine compound and application as melanocortin receptor agonist | |
EP3442543A4 (en) | Compositions and methods for neuralgenesis | |
EP3436083A4 (en) | Novel compositions and methods | |
EP3096757A4 (en) | Apilimod compositions and methods for using same | |
EP3319938A4 (en) | Small molecule inhibitors of the mcl-1 oncoprotein and uses thereof | |
EP3230302A4 (en) | Carrier molecule compositions and related methods | |
EP3253389A4 (en) | Apilimod compositions and methods for using same | |
EP3706558A4 (en) | Compositions and methods for aquaculturing | |
EP3217978A4 (en) | Compositions comprising substituted benzofuroquinolizine and alpha2-adrenergic agonists | |
EP3191483A4 (en) | Compounds as crth2 antagonist and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20171113 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: 7 HILLS INTERESTS, LLC Owner name: TEXAS HEART INSTITUTE |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/16 20060101ALI20181213BHEP Ipc: A61K 39/39 20060101ALI20181213BHEP Ipc: A61K 31/381 20060101ALI20181213BHEP Ipc: A61K 39/00 20060101AFI20181213BHEP Ipc: A61K 31/36 20060101ALI20181213BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20190401 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/36 20060101ALI20190326BHEP Ipc: A61K 31/381 20060101ALI20190326BHEP Ipc: A61K 39/00 20060101AFI20190326BHEP Ipc: A61K 39/39 20060101ALI20190326BHEP Ipc: A61K 31/16 20060101ALI20190326BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20200616 |
|
R17C | First examination report despatched (corrected) |
Effective date: 20200717 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |